Mobile Marketing Platform YouAppi and Xsolla Announce a New Program to Help Mobile Game Developers Grow Their Business
24.5.2023 11:00:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, announced today that they are launching a partnership with YouAppi, the leading mobile marketing platform for global brands wanting to grow their business. The collaboration aims to address the needs of the gaming market by providing retargeting campaigns that help mobile game developers and publishers drive more players to a web shop and grow revenue from existing players.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005134/en/
Mobile Advertising With YouAppi (Graphic: Business Wire)
YouAppi and Xsolla's partnership will transform the game industry business and portfolio strategies for revenue growth and retention to their partners. Xsolla and YouAppi joined forces to help video game developers and publishers retain, retarget and re-engage mobile app users and to amplify what Xsolla Web Shop already does well - it helps to increase the average purchase amount, the number of repeated purchases and re-engage with consumers who have not recently played the game.
"Today, we're proud to announce a game-changing alliance between Xsolla and YouAppi, the leading mobile marketing platform for brands seeking exponential growth, said Chris Hewish, President of Xsolla. "Our joint mission is to revolutionize how video game developers and publishers engage with mobile app users, optimizing retention, retargeting, and re-engagement strategies. By synergizing our efforts, we're amplifying the strengths of Xsolla Web Shop, which already excels in boosting average purchase amounts, repeat purchases, and transitioning traffic from mobile to web."
Web Shop is a direct-to-consumer commerce solution powered by Xsolla for mobile games. Sell in-game items, currencies, and top-up player accounts online, inspire players to purchase, keep more of your revenue, and boost LTV and ARPU, all from your website.
"The Xsolla and YouAppi partnership is a powerful combination. Xsolla's understanding of increasing user monetization through its Web Shop uniquely complements YouAppi's ability to increase user retention through mobile app retargeting," said Moshe Vaknin, CEO of YouAppi. "This will be an industry-leading collaboration."
For more information about the Mobile Advertising platform, please visit: https://xsolla.pro/youappi
About YouAppi
YouAppi is a leading growth and retention platform for mobile apps, specializing in re-engagement and retargeting. Powered by machine learning and audience targeting, YouAppi’s proven proprietary app remarketing technology finds and retains the most profitable users for its clients. YouAppi works with mobile app companies across the globe in gaming, e-commerce, entertainment, lifestyle, and finance among others. Established in 2011, YouAppi has been a long-term partner to leading mobile advertisers, earning recent awards including top 100 fastest-growing companies in North America on the 2021 Deloitte Technology Fast 500™ and 2023 Inc. 5000 Regionals: Pacific list. YouAppi is also ranked a global top 10 remarketing company on the Appsflyer 2022 performance index in gaming and non-gaming. To learn more, visit: www.youappi.com.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, Beijing, Kuala Lumpur, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005134/en/
Contact information
Derrick Stembridge
Global Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom